ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reported financial results and reviewed business highlights for the three-month period ended September 30, 2016.
“During the last quarter, we strengthened our business and better positioned ImmunoGen for long-term growth,” said Mark Enyedy, president and chief executive officer of ImmunoGen.
“During the last quarter, we strengthened our business and better positioned ImmunoGen for long-term growth,” said Mark Enyedy, president and chief executive officer of ImmunoGen.